News

Study results suggest C4d is associated with worse renal survival and disease progression to kidney failure in patients with primary IgA nephropathy.

Lp(a) ordering remains low in patients at risk for ASCVD, particularly non-Hispanic Black or Hispanic individuals in socioeconomically disadvantaged neighborhoods.

This interview with Culton featured a discussion of key challenges faced when treating patients with blistering diseases such as pemphigus and bullous pemphigoid.

A study revealed erenumab at 140 mg is effective and safe in achieving remission of headaches caused by non-opioid medication overuse.

In this segment of his interview, Zirwas highlighted the use of JAK inhibitors such as upadacitinib, discussed safety, and touched on topical options for patients with eczema.

Positive topline results from the phase 2a HERALD study of ALG-055009 in MASH highlight the THR-β agonist’s impact on liver fat reduction.

EDG-7500 was well-tolerated in healthy patients in Phase 1 while achieving gradient relief without LVEF reductions in the Phase 2 CIRRUS-HCM trial.

Shapiro spoke in his Maui Derm NP+PA Fall conference interview about differentiating between types of alopecia areata and about the potential use of JAK inhibitors.

The model Revised REACH-B outperforms an earlier model by incorporating predictors of predictors of age, sex, platelet count, ALT levels, and positive hepatitis B antigen result.

High-risk SAFE scores were linked to increased mortality, especially in participants with alcohol-associated liver disease, as this group demonstrated the worst survival.

Ferric carboxymaltose achieved superior outcomes to an oral iron tablet for the treatment of anemia in pregnant women.

Zirwas described several highlights from his presentation on updates in managing atopic dermatitis, describing examples such as lebrikizumab and nemolizumab.

Inpatients receiving brief cognitive behavioral therapy had a 60% reduced likelihood of suicide attempts and a 71% reduced rate of psychiatric readmissions post-discharge.

The new guidance reviews existing tools for weight management and provides recommendations for their use in clinical practice in patients with obesity and kidney disease.

Amanda Wilson, PhD, details how her team is developing risk assessment models to evaluate viral infection intervention in schools.

In her Maui Derm NP+PA Fall interview, Harper highlighted treatment approaches and unmet needs of patients with acne.

Georgios Kitsios, MD, PhD, discusses his team's interim results an analysis that is providing insights into the microbiome dynamics of critically ill patients with VAP.

Kerri Aronson, MD, MS, describes her team's research efforts to create educational resources that address the profound lack of patient knowledge around HP.

After his review on recent literature, Zirwas’s Maui Derm NP+PA Fall interview featured a discussion about the biggest unmet needs among patients.

The IL-23 inhibitor lowered the risk of uveitis more than TNF-α inhibitors in patients with moderate to severe psoriasis.

The FDA has approved the Eversense 365, the world’s first 1-year continuous glucose monitor, with US availability expected in late 2024.

A report shows only 24%, 56%, and 62% of patients meet the criteria PSIL-AT for depression according to low-bound, mid-range, and upper-bound estimates, respectively.

At Maui Derm NP+PA Fall 2024, bimekizumab data demonstrates a consistent safety profile in moderate to severe plaque psoriasis over 4 years, with decreasing event rates over time.

This interview featured a literature review discussion about non-FDA approved advancements in dermatology, including oral roflumilast for psoriasis, metformin for acne, and minoxidil for nails.

Moser reviews ongoing unmet needs in PBC and how the addition of 2 new second-line treatment options has changed the treatment landscape.

In this interview segment, Chovatiya highlights HS therapies such as IL-17 inhibitors and JAK inhibitors, as well as unmet needs of patients.

A new study revealed those who consume a moderate amount of coffee or caffeine had a 48.1% and 40.7% reduced risk for developing cardiometabolic multimorbidity.

This interview with Chovatiya highlights promising therapies in the dermatology space for the treatment of patients with the skin condition HS.